Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Mereo reported a Q2 net loss of $7.0 million, narrowed from $14.6 million in the prior year, with cash and cash equivalents of $30.1 million now expected to fund operations into late 2027. The company announced an option and license agreement with Sentynl Therapeutics for alvelestat, potentially generating $40 million in upfront payments and up to $435 million in milestones if the option is exercised.
Key figures
- Revenue
- 0
- Runway
- late-2027
- Net loss
- 7000000
- Ga expenses
- 5200000
- Rd expenses
- 1800000
- Deal upfront
- 40000000
- Cash position
- 30100000
- Deal milestones
- 435000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.